The Experts in Animal Health

Brakke Consulting’s
Animal Health News & Notes for October 14, 2022
Copyright © Brakke Consulting
Editor: Lynn Fondon DVM MBA


Brakke Consulting News
2022 Flea Control & Heartworm Markets report – pre-order now

Earnings News

Other News
Clayton, Dubilier & Rice
Dechra (Meloxoral)
Dechra (Strangvac)
Get Joy
Hill’s Pet Nutrition
L Catterton
Merck (Allflex DataFlow II)
Merck (Mometamax Ultra)
Oncotelic Therapeutics
Ondax Scientific
Purina PetCare
Spot Pet Insurance
Torigen Pharmaceuticals
TPG Capital
Vidium Animal Health


Are you on top of the trends in the largest market segment in companion animal health?  Brakke Consulting will soon be publishing our 2022 report on the  US Flea Control and Heartworm Markets.

The report includes valuable information on the US market for small animal parasiticides including:

– Product descriptions, prices (veterinarian cost and online pricing), and sales for the leading veterinary flea, tick and heartworm products
– an overview of the veterinary and OTC flea control markets
– discussion of new product launches

– 2022 survey of 300+ veterinarians
– 2022 survey of 500 pet owners

The US Flea Control & Heartworm Markets report will be available for a purchase price of $7,495 if ordered by FRIDAY, NOVEMBER 18, and $7,995 after that date.

Please contact Dr. Lynn Fondon at 336-396-3916 or to pre-order the report, or for more information visit our website.


  • Vetoquinol SA reported results for the third quarter of 2022. Revenues were EUR 134 million ($130 million), a 1.5% increase in third-quarter revenues (decline of 4.5% on a constant currency basis). The firm’s European division recorded an 8% decline in revenues; its Americas and Asia Pacific divisions both grew by 10%. (IHS Markit Connect – subscription)


  • Merck Animal Health announced the launch of the Allflex DataFlow II System mobile app as part of its livestock intelligence portfolio of digital products. The app integrates with the Allflex DataFlow II System on the producer’s desktop. (Feedstuffs – subscription)
  • Covetrus announced the successful completion of its previously announced acquisition by funds affiliated with Clayton, Dubilier & Rice and TPG Capital. As a result of the transaction, Covetrus is now a private company, and its stock is no longer publicly listed or traded on NASDAQ. Financial terms were not disclosed. (company press release)
  • Neogen Corporation announced that it has added Companion RTU, a ready-to-use formulation of its Companion disinfectant, to its veterinary biosecurity portfolio. Companion RTU is a combination of quaternary ammonium and glutaraldehyde dual-active disinfectant that kills both Gram-negative and Gram-positive bacteria, fungi, and viruses. (com)
  • Purina PetCare has partnered with Spot Pet Insurance to introduce Spot Pet Insurance to more pet owners across Purina’s consumer base. Through the partnership, Spot Pet Insurance will offer a discount of up to 10%, as well as a 10% multi-pet discount for pets added to an existing insurance plan, to select Purina customers. (Petfood Processing – subscription)
  • Hill’s Pet Nutrition announced the launch of its new education platform, Hill’s Veterinary Academy, which will provide virtual continuing education opportunities for veterinary teams. (PRNewswire)
  • Vidium Animal Health announced that it has partnered with Torigen Pharmaceuticals to offer genomic testing and precision medicine to more veterinarians. Torigen’s sales team will now include Vidium’s SearchLight DNA genomic diagnostic test alongside the company’s personalized cancer immunotherapies in its precision medicine portfolio. (Yahoo)
  • Oncotelic Therapeutics, Inc., a developer of treatments for rare and orphan indications, announced the formation of an animal health division. (Globenewswire)
  • Yummers announced it has raised $6.3 million in a seed funding round led by L Catterton and other investors. The omnichannel pet lifestyle brand – whose portfolio currently includes 18 meal mix-in varieties for dogs and cats – will use the new capital to support its brand strategy and retail partnership with Petco. (Petfood Processing – subscription)
  • Direct-to-consumer dog food company Get Joy announced the launch of Get Joy Health, bringing on-demand information from licensed veterinary professionals to pet owners. Get Joy Health is available free of charge to all active Get Joy subscribers. (Pet Business)
  • EU The Committee for Veterinary Medicinal Products of the European Medicines Agency (EMA) has recommended marketing authorization for Merck‘s Mometamax Ultra ear drops (gentamicin, posaconazole and mometasone furoate) for dogs to treat otitis externa caused by mixed infections with bacteria and fungi. (IHS Markit Connect – subscription)
  • EU The Committee for Veterinary Medicinal Products of the European Medicines Agency (EMA) has recommended marketing authorization for Dechra Pharmaceutical‘s Meloxoral (meloxicam) chewable tablets for dogs . (IHS Markit Connect – subscription)
  • EU Intervacc announced it has rolled out its Strangvac equine strangles vaccine in six additional EU countries: Germany, France, Austria, Belgium, Luxembourg and the Netherlands. Previously Intervacc announced that Dechra Pharmaceuticals would be the exclusive distributor of Strangvac throughout Europe (excluding certain Nordic and Baltic countries). (IHS Markit Connect – subscription)
  • SPAIN Argenta announced it has acquired Spanish firm Ondax Scientific for an undisclosed fee. The deal – Argent’s third European purchase in the past two years – expands Argenta’s contract research footprint further into southern and western Europe. (IHS Markit Connect – subscription)


* Covetrus’ acquisition by Clayton, Dubilier & Rice and TPG Capital was finalized and will no longer be included in the stock price table after today.*


  • US – AGDUFA The FDA will hold a public meeting on October 26, 2022, to offer opportunity for discussion on the proposed recommendations for reauthorization of the Animal Generic Drug User Fee Act (AGDUFA). Interested parties can share their comments at the meeting or by submitting them to the public docket electronically or by mail. Stakeholders interested in attending this public meeting must register online no later than October 24, 2022. (FDA)
  • US – FELINE UROLITHIASIS The American Association of Feline Practitioners (AAFP) has released the 2022 AAFP Consensus Statement on the Approaches to Urolithiasis Treatment. The Consensus Statement provides patient-centered, research, and experience-supported recommendations for the treatment of cystoliths in cats.  (association press release)
  • US – RABIES GUIDANCE AVMA announced it has updated its model document for rabies control laws. Among other changes, the updated AVMA Model Rabies Control Document indicates for the first time that horses and other equids should be vaccinated against rabies. It also provides differentiated guidance for post-exposure management of companion animals believed to have been exposed to rabies, depending on their rabies vaccination status. (association press release)


Pet insurance has been available in the USA for more than four decades, and yet the latest statistics from the North American Pet Health Insurance Association (NAPHIA) say that only about 4 million pets in the USA are insured – that’s only 4% of dogs, and a mere 1% of cats. That stands in stark contrast to some other countries; for example, in the UK 61% of dogs and one-third of cats are covered by health insurance; and in Sweden 9 out of 10 dogs, and half of all cats, are reportedly insured.

A higher proportion of insured pets would be a plus for the veterinary profession – more pet owners able to afford the kind of “gold standard” care that all veterinarians wish for their patients.  The good news is that growth in insured pets is outpacing overall growth in the pet population. NAPHIA reports that average annual growth in the number of insured pets in the USA since 2017 has exceeded 20%, and the pace is accelerating: in 2021 the growth was close to 30%.  Maybe we can only aspire to reach coverage levels in the UK or Sweden, but we’re moving in the right direction.

Lynn Fondon


Last week, we asked you to pick the most important and impactful trend to be addressed regarding hybrid work.  42% of you said “flexible work is here to stay”; 28% said “leaders are out of touch with employees and need a wake-up call”; and 18% said “high productivity is masking an exhausted workforce.”  7% said “talent is everywhere in the hybrid world” and 5% said “Gen Z is at high risk and will need to be energized.”

This week

Two weeks ago, Zoetis announced the US launch of Solensia, a once-monthly monoclonal antibody injection for treating osteoarthritis in cats. It’s been available in Europe since 2021. Let’s hear from you about whether you think that Solensia will be the blockbuster that Zoetis believes it is.

In the next 5 years, will Solensia reach blockbuster status ($100 million in global sales)?

en_USEnglish (United States)